Dimethyl Fumarate: A Review in Relapsing-Remitting MS

Drugs

Volumn 76, Issue 2, 2016, Pages 243-254

  Deeks, Emma D ^a  

^a SPRINGER   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA1A INTERFERON; FUMARIC ACID DIMETHYL ESTER; FUMARIC ACID METHYL ESTER; GADOLINIUM; GLATIRAMER; ORAL CONTRACEPTIVE AGENT; PLACEBO; IMMUNOSUPPRESSIVE AGENT;

COST EFFECTIVENESS ANALYSIS; DIARRHEA; DISEASE ACTIVITY; DRUG EFFICACY; DRUG TOLERABILITY; ELIMINATION HALF-LIFE; EXPANDED DISABILITY STATUS SCALE; FLUSHING; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNOMODULATION; LONG TERM CARE; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MAXIMUM PLASMA CONCENTRATION; MULTIPLE SCLEROSIS; NAUSEA; NEUROIMAGING; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIA; OXIDATIVE STRESS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PHYSICAL DISABILITY; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; RELAPSE; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOLUME OF DISTRIBUTION; DISEASE COURSE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; ORAL DRUG ADMINISTRATION; PROCEDURES;

ADMINISTRATION, ORAL; CLINICAL TRIALS, PHASE III AS TOPIC; DIMETHYL FUMARATE; DISEASE PROGRESSION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS, RELAPSING-REMITTING;

EID: 84954400449     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-015-0528-1     Document Type: Review

References (92)

1. National Institute of Neurological Disorders and Stroke. Multiple sclerosis: hope through research. 2015. http://www.ninds.nih.gov/disorders/multiple-sclerosis/detail-multiple-sclerosis.htm. Accessed 3 Dec 2015.
2. National Multiple Sclerosis Society. What is MS? 2015. http://www.nationalmssociety.org. Accessed 3 Dec 2015.
3. Ortiz GG, Pacheco-Moises FP, Bitzer-Quintero OK, et al. Immunology and oxidative stress in multiple sclerosis: clinical and basic approach. Clin Dev Immunol. 2013;2013:708659.
4. Kim W, Zandona ME, Kim SH, et al. Oral disease-modifying therapies for multiple sclerosis. J Clin Neurol. 2015;11(1):9-19.
5. Gajofatto A, Benedetti MD. Treatment strategies for multiple sclerosis: when to start, when to change, when to stop? World J Clin Cases. 2015;3(7):545-55.
6. ® (dimethyl fumarate) delayed-release capsules: US prescribing Information. 2014. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm. Accessed 3 Dec 2015.
7. Biogen Idec Ltd. Tecfidera gastro-resistant hard capsules: EU summary of product characteristics. 2015. http://www.ema.europa.eu/ema/. Accessed 3 Dec 2015.
8. Burness CB, Deeks ED. Dimethyl fumarate: a review of its use in patients with relapsing-remitting multiple sclerosis. CNS Drugs. 2014;28(4):373-87.
9. Scannevin RH, Chollate S, Jung MY, et al. Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway. J Pharmacol Exp Ther. 2012;341(1):274-84.
10. Linker RA, Lee DH, Ryan S, et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain. 2011;134(Pt 3):678-92.
11. Wang Q, Chuikov S, Taitano S, et al. Dimethyl fumarate protects neural stem/progenitor cells and neurons from oxidative damage through Nrf2-ERK1/2 MAPK pathway. Int J Mol Sci. 2015;16(6):13885-907.
12. Lin SX, Lisi L, Russo CD, et al. The anti-inflammatory effects of dimethyl fumarate in astrocytes involve glutathione and haem oxygenase-1. ASN Neuro. 2011;3(2).
13. Albrecht P, Bouchachia I, Goebels N, et al. Effects of dimethyl fumarate on neuroprotection and immunomodulation. J Neuroinflamm. 2012;9:163.
14. Huang H, Taraboletti A, Shriver LP. Dimethyl fumarate modulates antioxidant and lipid metabolism in oligodendrocytes. Redox Biol. 2015;5:169-75.
15. Schulze-Topphoff U, Varrin-Doyer M, Pekarek K, et al. Dimethyl fumarate utilizes NRF2-independent and NRF2-dependent pathways for immune modulation [abstract no. S53.002]. Neurology. 2014;82(10 Suppl).
16. Chen H, Assmann JC, Krenz A, et al. Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarate's protective effect in EAE. J Clin Invest. 2014;124(5):2188-92.
17. Parodi B, Rossi S, Morando S, et al. Fumarates modulate microglia activation through a novel HCAR2 signaling pathway and rescue synaptic dysregulation in inflamed CNS. Acta Neuropathol (Berl). 2015;130(2):279-95.
18. Tang H, Lu JY, Zheng X, et al. The psoriasis drug monomethylfumarate is a potent nicotinic acid receptor agonist. Biochem Biophys Res Commun. 2008;375(4):562-5.
19. Hanson J, Gille A, Zwykiel S, et al. Nicotinic acid- and monomethyl fumarate-induced flushing involves GPR109A expressed by keratinocytes and COX-2-dependent prostanoid formation in mice. J Clin Invest. 2010;120(8):2910-9.
20. Wilms H, Sievers J, Rickert U, et al. Dimethylfumarate inhibits microglial and astrocytic inflammation by suppressing the synthesis of nitric oxide, IL-1beta, TNF-alpha and IL-6 in an in vitro model of brain inflammation. J Neuroinflamm. 2010;7:30.
21. Ghoreschi K, Bruck J, Kellerer C, et al. Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells. J Exp Med. 2011;208(11):2291-303.
22. Peng H, Guerau-de-Arellano M, Mehta VB, et al. Dimethyl fumarate inhibits dendritic cell maturation via nuclear factor kappaB (NF-kappaB) and extracellular signal-regulated kinase 1 and 2 (ERK1/2) and mitogen stress-activated kinase 1 (MSK1) signaling. J Biol Chem. 2012;287(33):28017-26.
23. Schilling S, Goelz S, Linker R, et al. Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration. Clin Exp Immunol. 2006;145(1):101-7.
24. Schimrigk S, Brune N, Hellwig K, et al. Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study. Eur J Neurol. 2006;13(6):604-10.
25. Peng H, Matos M, Wipke B, et al. Dimethyl fumarate alters microglia phenotype and protects neurons against proinflammatory toxic microenvironments [abstract no. P1.163]. Neurology. 2015;84(14 Suppl).
26. Brenna M, Matos M, Sun C, et al. The NRF2 transcriptional target, OSGIN1, contributes to the cytoprotective properties of monomethyl fumarate [abstract no. P1.150]. Neurology. 2015;84(14 Suppl).
27. Phillips JT, Fox RJ. BG-12 in multiple sclerosis. Semin Neurol. 2013;33(1):56-65.
28. Brennan M, Allaire N, Huss D, et al. Dimethyl fumarate and monomethyl fumarate are distinguished by non-overlapping pharmacodynamic effects in vivo [abstract no. P1.206]. Neurology. 2014;82(Suppl):10.
29. Brennan MS, Matos MF, Li B, et al. Dimethyl fumarate and monoethyl fumarate exhibit differential effects on KEAP1, NRF2 activation, and glutathione depletion in vitro. PLoS One. 2015;10(3):e0120254.
30. Gillard GO, Collette B, Anderson J, et al. DMF, but not other fumarates, inhibits NF-kappaB activity in vitro in an Nrf2-independent manner. J Neuroimmunol. 2015;283:74-85.
31. Treumer F, Zhu K, Glaser R, et al. Dimethylfumarate is a potent inducer of apoptosis in human T cells. J Invest Dermatol. 2003;121(6):1383-8.
32. Vandermeeren M, Janssens S, Wouters H, et al. Dimethylfumarate is an inhibitor of cytokine-induced nuclear translocation of NF-kappa B1, but not RelA in normal human dermal fibroblast cells. J Invest Dermatol. 2001;116(1):124-30.
33. Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. New Engl J Med. 2012;367(12):1098-107 (plus supplementary appendix).
34. Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. New Engl J Med. 2012;367(12):1087-97 (plus supplementary appendix).
35. Woodworth J, Zhao Z, Stecher S. Oral BG-12 in combination with interferon beta-1a or glatiramer acetate: pharmacokinetics, safety and tolerability [abstract]. 28th Congress of ECTRIMS and 15th Annual Conference of RIMS; 2010.
36. Sheikh SI, Nestorov I, Russell H, et al. Tolerability and pharmacokinetics of delayed-release dimethyl fumarate administered with and without aspirin in healthy volunteers. Clin Ther. 2013;35(10):1582-94.
37. Giovannoni G, Gold R, Fox RJ, et al. Delayed-release dimethyl fumarate and relapses requiring intravenous steroid use and MS-related hospitalizations: integrated analysis of the phase 3 DEFINE and CONFIRM studies [abstract no. PP1228]. J Neurol. 2014;261(Suppl 1):S303.
38. Gold R, Giovannoni G, Phillips JT, et al. Long-term efficacy of delayed-release dimethyl fumarate in newly diagnosed patients with RRMS: an integrated analysis of DEFINE, CONFIRM, and ENDORSE [abstract no. P7.227]. Neurology. 2015;84(14 Suppl).
39. Bar-Or A, Gold R, Fox RJ, et al. Five-year follow-up of delayed-release dimethyl fumarate in RRMS: integrated clinical efficacy data from the DEFINE, CONFIRM, and ENDORSE studies [abstract no. P7.234]. Neurology. 2015;84(14 Suppl).
40. Fernandez O, Giovannoni G, Fox RJ, et al. Efficacy of delayed-release dimethyl fumarate for RRMS in prior interferon users in the DEFINE and CONFIRM studies [abstract no. P7.231]. Neurology. 2015;84(14 Suppl).
41. Phillips JT, Gold R, Giovannoni G, et al. Clinical efficacy of delayed-release dimethyl fumarate in newly diagnosed relapsing-remitting multiple sclerosis patients with highly active disease: an integrated analysis of the phase 3 DEFINE and CONFIRM studies [abstract no. P7.228]. Neurology. 2015;84(14 Suppl).
42. Fernández Ó, Giovannoni G, Fox RJ, et al. Efficacy of delayed-release dimethyl fumarate for relapsing-remitting multiple sclerosis in prior interferon users with low clinical disease activity: integrated analysis of the phase 3 DEFINE and CONFIRM studies [abstract no. EP1318]. In: 31st Congress of ECTRIMS; 2015.
43. Yousry T, Arnold DL, Fox RJ, et al. Five-year follow-up of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: MRI outcomes from DEFINE, CONFIRM, and ENDORSE [abstract no. P7.262]. Neurology. 2015;84(14 Suppl).
44. Kappos L, Fox RJ, Gold R, et al. Delayed-release dimethyl fumarate and health-related quality of life (HRQoL) in relapsing-remitting multiple sclerosis (RRMS) patients according to prior therapy: integrated analysis of DEFINE and CONFIRM [abstract no. PP1238]. J Neurol. 2014;261(Suppl 1):S306.
45. Sarda SP, Kita M, Fox RJ, et al. An interim analysis of quality of life in patients with relapsing-remitting multiple sclerosis treated with delayed-release dimethyl fumarate [abstract no. P790]. Mult Scler. 2014;20(1 Suppl 1):413-4.
46. Kremenchutzky M, Fox RJ, Phillips JT, et al. Efficacy of delayed-release dimethyl fumarate vs glatiramer acetate on a novel composite outcome measure of inflammatory disease activity: post hoc analysis of the CONFIRM study [abstract no. P1063]. In: 31st Congress of ECTRIMS; 2015.
47. Gold R, Giovannoni G, Phillips JT, et al. Efficacy of delayed-release dimethyl fumarate in early multiple sclerosis: post hoc analysis of the phase 3 DEFINE and CONFIRM studies according to baseline disability [abstract no. P565]. In: ECTRIMS; 2015.
48. Miller D, Yousry T, Fox RJ, et al. Sustained low rate of brain volume loss with long-term delayed release dimethyl fumarate treatment in relapsing-remitting multiple sclerosis patients: results from the ENDORSE study [abstract no. P1072]. In: ECTRIMS; 2015.
49. Fox RJ, Chan A, Gold R, et al. Characterization of absolute lymphocyte count profiles in MS patients treated with delayed-release dimethyl fumarate: considerations for patient management [abstract no. P606]. In: ECTRIMS; 2015.
50. Miller DHF, Fox RJ, Phillips JT, et al. Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study. Neurology. 2015;84(11):1145-52.
51. Arnold DL, Gold R, Kappos L, et al. Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study. J Neurol. 2014;261(9):1794-802.
52. Viglietta V, Miller D, Bar-Or A, et al. Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials. Ann Clin Transl Neurol. 2015;2(2):103-18.
53. Kappos L, Giovannoni G, Gold R, et al. Time course of clinical and neuroradiological effects of delayed-release dimethyl fumarate in multiple sclerosis. Eur J Neurol. 2015;22(4):664-71.
54. Bar-Or A, Gold R, Kappos L, et al. Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study. J Neurol. 2013;260(9):2297-305.
55. Hutchinson M, Fox RJ, Miller DH, et al. Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study. J Neurol. 2013;260(9):2286-96.
56. Gold R, Giovannoni G, Phillips JT, et al. Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsing-remitting multiple sclerosis (RRMS). Mult Scler. 2015;21(1):57-66.
57. Arnold DL, Gold R, Kappos L, et al. Magnetization transfer ratio in the delayed-release dimethyl fumarate DEFINE study. J Neurol. 2014;261(12):2429-37.
58. Kappos L, Gold R, Arnold DL, et al. Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: the DEFINE study. Mult Scler. 2014;20(2):243-52.
59. Kita M, Fox RJ, Phillips JT, et al. Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study. Mult Scler. 2014;20(2):253-7.
60. Kita M, Fox RJ, Gold R, et al. Effects of delayed-release dimethyl fumarate (DMF) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: an integrated analysis of the phase 3 DEFINE and CONFIRM studies. Clin Ther. 2014;36(12):1958-71.
61. Gold R, Phillips JT, Havradova E, et al. Delayed-release dimethyl fumarate and pregnancy: preclinical studies and pregnancy outcomes from clinical trial and postmarketing experience. Neurol Ther. 2015. doi: 10.1007/s40120-015-0033-1.
62. Phillips JT, Selmaj K, Gold R, et al. Clinical significance of gastrointestinal and flushing events in patients with delayed-release dimethyl fumarate. Int J MS Care. 2015;17:236-43.
63. Phillips JT, Hutchinson M, Fox R, et al. Managing flushing and gastrointestinal events associated with delayed-release dimethyl fumarate: experiences of an international panel. Mult Scler Relat Disord. 2014 3(4):513-9.
64. Phillips JT, Erwin AA, Agrella S, et al. Consensus management of gastrointestinal events associated with delayed-release dimethyl fumarate: a Delphi study. Neurol Ther. 2015. doi: 10.1007/s40120-015-0037-x.
65. Von Hehn C, Tornatore C, Li J, et al. Effect of bismuth subsalicylate on gastrointestinal events associated with delayed-release dimethyl fumarate: a double-blind, placebo-controlled study [abstract no. P052]. Mult Scler. 2014;20(1 Suppl 1):90.
66. Tornatore C, Amjad F. Attenuation of dimethyl fumarate-related gastrointestinal symptoms with montelukast [abstract P7.251 plus poster]. Neurology. 2014;82(10 Suppl).
67. Sammarco C, Laing L, Herbert J. Strategies to reduce adverse events related to oral dimethyl fumarate [abstract no. P311 plus poster]. Mult Scler. 2014;20(1 Suppl 1):206.
68. Begus-Nahrmann Y, Niemczyk G, Schmid B, et al. Disparities and challenges to oral disease modifying MS therapies and the potential of individualised coaching [poster no. P1121]. In: 31st Congress of ECTRIMS; 2015.
69. Fox EJ, Vasquez A, Grainger W, et al. Gastrointestinal tolerability of dimethyl fumarate in a multicenter, open-label study of patients with relapsing forms of multiple sclerosis (MANAGE). Int J MS Care. 2015. doi: 10.7224/1537-2073.2014-101.
70. O'Gorman J, Russell HK, Li J, et al. Effect of aspirin pretreatment or slow dose titration on flushing and gastrointestinal events in healthy volunteers receiving delayed-release dimethyl fumarate. Clin Ther. 2015;37(7):1402-19.
71. Fox R, Gold R, Phillips JT, et al. Lymphocyte count reductions in relapsing-remitting multiple sclerosis (RRMS) patients treated with delayed-release dimethyl fumarate: an integrated analysis of the placebo-controlled studies [abstract]. Neurology. 2014;82(10 Suppl 1).
72. European Medicines Agency. Updated recommendations to minimise the risk of the rare brain infection PML with Tecfidera [media release]. http://www.ema.europa.eu/. Accessed 23 Oct 2015.
73. Lima MA. Progressive multifocal leukoencephalopathy: new concepts. Arq Neuropsiquiatr. 2013;71(9B):699-702.
74. McKee S. Biogen reports second case of PML [media release]. http://pharmatimes.com. Accessed 20 Jul 2015.
75. Rosenkranz T, Novas M, Terborg C. PML in a patient with lymphocytopenia treated with dimethyl fumarate. N Engl J Med. 2015;372(15):1476-8.
76. Pozzilli C, Phillips JT, Fox R, et al. Long-term follow-up of the safety of delayed-release dimethyl fumarate in RRMS: interim results from the ENDORSE extension study [abstract no. P066 plus poster]. Neurology. 2015;84(14 Suppl):96-7.
77. Costello K, Halper J, Kalb R, et al. The use of disease-modifying therapies in multiple sclerosis: principles and current evidence. 2015. http://www.nationalmssociety.org. Accessed 3 Dec 2015.
78. Canadian Agency for Drugs and Technology in Health. CADTH therapeutic review: recommendations for drug therapies for relapsing-remitting multiple sclerosis. 2013. https://www.cadth.ca/media/pdf/TR0004-RRMS-RecsReport-TR-e.pdf. Accessed 3 Dec 2015.
79. Biogen. Gastrointestinal tolerability study of dimethyl fumarate (DMF) in participants with relapsing-remitting multiple sclerosis in Germany (TOLERATE). ClinicalTrials.gov identifier NCT02125604. 2015. https://www.clinicaltrials.gov. Accessed 3 Dec 2015.
80. Tornatore C, Walsh J, Mann M, et al. Effect of montelukast on gastrointestinal tolerability in patients with relapsing forms of multiple sclerosis receiving delayed-release dimethyl fumarate: a multicenter, randomized, double-blind, placebo-controlled study (MITIGATE) [abstract no. P1.127]. Neurology. 2015;84(14 Suppl).
81. Thomas RH, Wakefield RA. Oral disease-modifying therapies for relapsing-remitting multiple sclerosis. Am J Health-System Pharm. 2015;72(1):25-38.
82. MS-UK Helpline. Oral MS medications 'don't improve treatment adherence'. 2015. http://www.ms-uk.org/drugsresearch. Accessed 24 Aug 2015.
83. Scolding N, Barnes D, Cader S, et al. Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis. Pract Neurol. 2015;15(4):273-9.
84. Cohn S, Bermel R, Hara C, et al. Comparative tolerability and efficacy of dimethyl fumarate and fingolimod in multiple sclerosis [abstract no. P300]. Mult Scler. 2014;20(1 Suppl 1):201.
85. Nixon R, Bergvall N, Tomic D, et al. No evidence of disease activity: indirect comparisons of oral therapies for the treatment of relapsing-remitting multiple sclerosis. Adv Ther. 2014;31(11):1134-54.
86. Hutchinson M, Fox RJ, Havrdova E, et al. Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison. Curr Med Res Opin. 2014;30(4):613-27.
87. National Institute for Health and Care Excellence. NICE technology appraisal guidance TA32, TA320, TA303 and TA254. 2002-2014. https://www.nice.org.uk. Accessed 3 Dec 2015.
88. Zhang X, Hay JW, Niu X. Cost effectiveness of fingolimod, teriflunomide, dimethyl fumarate and intramuscular interferon-beta1a in relapsing-remitting multiple sclerosis. CNS Drugs. 2015;29(1):71-81.
89. Maruszczak MJ, Montgomery SM, Griffiths MJ, et al. Cost-utility of fingolimod compared with dimethyl fumarate in highly active relapsing-remitting multiple sclerosis (RRMS) in England. J Med Econ. 2015;18(11):874-85.
90. Iyer R, Sussman M, Fay M, et al. Association between time to treatment initiation of delayed-release dimethyl fumarate following MS diagnosis and medical costs in a real-world setting [poster no. P331]. In: 31st Congress of ECTRIMS; 2015.
91. Cohan SL, LaGanke C, Tornatore C, et al. Real-world clinical outcomes in relapsing-remitting multiple sclerosis patients who switch from natalizumab to delayed-release dimethyl fumarate: preliminary analysis of a multicenter, retrospective, observational study (STRATEGY) [poster no. 3278]. Annual Meeting of the Consortum of Multiple Sclerosis Centers; 2015.
92. Viglietta V, Vollmer T, Zhang R, et al. Safety and tolerability of delayed-release dimethyl fumarate administered as add on therapy to beta interferons or glatiramer acetate in relapsing-remitting multiple sclerosis (RRMS) patients [abstract]. Neurology. 2014;82(10 Suppl. 1).